ClinicalTrials.gg
Drug

Allogeneic Invariant Natural Killer T-cells agenT-797 clinical trials

Also written agenT-797.

Its developmentBy Agenus, MiNK Therapeutics and ImmunityBio, step by step5 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.
studies test it
8
open now
3
in phase 3
0
first study started
2020

How each study uses Allogeneic Invariant Natural Killer T-cells agenT-797 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Allogeneic Invariant Natural Killer T-cells agenT-797 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

agenT-797
7

Studies by the year they started

8 studies that test it; most in 2026 (4)

Studies that test Allogeneic Invariant Natural Killer T-cells agenT-797, by start year
YearStudies
20201
20211
20221
20241
20264

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 5 · Other 3

MiNK Therapeutics (4) · Memorial Sloan Kettering Cancer Center (1) · University of Wisconsin, Madison (1) · Darren Sigal, MD (1) · ImmunityBio, Inc. (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test Allogeneic Invariant Natural Killer T-cells agenT-797.

Studies

Open first, then newest update. How each study uses Allogeneic Invariant Natural Killer T-cells agenT-797 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 8

What changed recently

From the registry's own updates since Oct 19, 2026.

Started recruiting1